Brady Davis - Champions Oncology President
| CSBR Stock | USD 4.83 0.13 2.62% |
President
Brady Davis is President of Champions Oncology
| Address | One University Plaza, Hackensack, NJ, United States, 07601 |
| Phone | 201 808 8400 |
| Web | https://www.championsoncology.com |
Champions Oncology Management Efficiency
The company has return on total asset (ROA) of (0.1748) % which means that it has lost $0.1748 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.8865) %, meaning that it created substantial loss on money invested by shareholders. Champions Oncology's management efficiency ratios could be used to measure how well Champions Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/11/2024, Return On Tangible Assets is likely to drop to -0.15. In addition to that, Return On Capital Employed is likely to drop to -0.33. At this time, Champions Oncology's Total Assets are relatively stable compared to the past year. As of 05/11/2024, Non Current Assets Total is likely to grow to about 17.9 M, while Intangible Assets are likely to drop slightly above 650.6 K.Similar Executives
| Found 1 records | PRESIDENT Age | ||
| AmirAli Talasaz | Guardant Health | 44 | |
Management Performance
| Return On Equity | -3.89 | ||||
| Return On Asset | -0.17 |
Champions Oncology Leadership Team
Elected by the shareholders, the Champions Oncology's board of directors comprises two types of representatives: Champions Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Champions. The board's role is to monitor Champions Oncology's management team and ensure that shareholders' interests are well served. Champions Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Champions Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marianna Zipeto, Research Commercial | ||
| Michael MBA, Chief Officer | ||
| Maria Mancini, Chief Operations | ||
| Karin Heidemann, Executive Operations | ||
| Ronnie MD, CEO Director | ||
| Arthur Hanson, Vice Technology | ||
| BS CMAR, Ex Operations | ||
| David MBA, Chief Officer | ||
| Brady Davis, President | ||
| MBA MS, VP Marketing |
Champions Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Champions Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.89 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 68.93 M | ||||
| Shares Outstanding | 13.59 M | ||||
| Shares Owned By Insiders | 25.55 % | ||||
| Shares Owned By Institutions | 42.33 % | ||||
| Number Of Shares Shorted | 59.65 K | ||||
| Price To Earning | 220.00 X |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Champions Stock
| 0.69 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Moving against Champions Stock
| 0.75 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.69 | XFOR | X4 Pharmaceuticals | PairCorr |
| 0.49 | ELDN | Eledon Pharmaceuticals | PairCorr |
| 0.49 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
| 0.48 | FBRX | Forte Biosciences Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.Note that the Champions Oncology information on this page should be used as a complementary analysis to other Champions Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Champions Stock analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Champions Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Champions Oncology. If investors know Champions will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Champions Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.29) | Earnings Share (0.72) | Revenue Per Share 3.634 | Quarterly Revenue Growth (0.06) | Return On Assets (0.17) |
The market value of Champions Oncology is measured differently than its book value, which is the value of Champions that is recorded on the company's balance sheet. Investors also form their own opinion of Champions Oncology's value that differs from its market value or its book value, called intrinsic value, which is Champions Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Champions Oncology's market value can be influenced by many factors that don't directly affect Champions Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Champions Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Champions Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Champions Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.